Nothing Special   »   [go: up one dir, main page]

Casadevall et al., 2021 - Google Patents

SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities

Casadevall et al., 2021

View HTML
Document ID
13049979177043870864
Author
Casadevall A
Henderson J
Joyner M
Pirofski L
et al.
Publication year
Publication venue
The Journal of clinical investigation

External Links

Snippet

In recent months, genomic characterization of pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) isolates identified viral variants that are less susceptible to neutralization by convalescent plasma (CP), vaccine-elicited plasma/sera, or SARS-CoV-2 …
Continue reading at www.jci.org (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/32—Medical data management, e.g. systems or protocols for archival or communication of medical images, computerised patient records or computerised general medical references
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form

Similar Documents

Publication Publication Date Title
Casadevall et al. SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities
Chakraborty et al. SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options.
Bishop Potential and emerging treatment options for Ebola virus disease
Yi et al. COVID-19: what has been learned and to be learned about the novel coronavirus disease
Ianevski et al. Potential antiviral options against SARS-CoV-2 infection
Dayal et al. Connecting BCG vaccination and COVID-19: additional data
Wong et al. The management of coronavirus infections with particular reference to SARS
Casadevall et al. SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern
Burkert et al. Coronavirus disease 2019: clinics, treatment, and prevention
Haddad et al. A comprehensive review on the efficacy of several pharmacologic agents for the treatment of COVID-19
Piyush et al. Convalescent plasma therapy: a promising coronavirus disease 2019 treatment strategy
Zhang et al. SARS-CoV-2: an updated review highlighting its evolution and treatments
Hejaz Palestinian strategies, guidelines, and challenges in the treatment and management of coronavirus disease-2019 (COVID-19)
Baldeón et al. Effect of convalescent plasma as complementary treatment in patients with moderate COVID‐19 infection
Prabhu et al. Cyanobacterial metabolites as novel drug candidates in corona viral therapies: A review
Buisson Covid-19, an unfinished story
Lacombe et al. COVID-19 convalescent plasma to treat hospitalised COVID-19 patients with or without underlying immunodeficiency: a randomized trial
Yang et al. In silico de novo curcuminoid derivatives from the compound library of natural products research laboratories inhibit COVID-19 3CLpro activity
Sarker et al. A comprehensive overview of the newly emerged COVID-19 pandemic: features, origin, genomics, epidemiology, treatment, and prevention
Kandula et al. Effectiveness of COVID-19 convalescent plasma (CCP) during the pandemic era: A literature review
Rössler et al. Neutralization profile of Omicron variant convalescent individuals
Ch et al. Association of vaccine medication for the efficacious COVID-19 treatment
Boregowda et al. Comprehensive literature review and evidence evaluation of experimental treatment in COVID 19 contagion
Miravalle et al. Encephalitis complicating smallpox vaccination
Liu et al. Isolation and comparative analysis of antibodies that broadly neutralize sarbecoviruses